使用非阿片类镇痛药的多模式干预与住院炎症性肠病患者静脉阿片类药物暴露减少相关
这项前瞻性评估在2019年1月1日至6月30日对某大型城市学术医学中心普通内科病房住院的≥18岁炎症性肠病(IBD)患者实施鼓励使用非阿片类替代药物的多模式干预,并与2018年全年干预前数据比较。结果显示干预期间接受静脉阿片类药物(IVOPI)的患者比例、总阿片类药物剂量、平均住院时间和30天再入院率均显著降低,而平均疼痛评分相似。
要点
- 多模式干预与IBD住院患者静脉阿片类药物暴露比例降低相关(43.6% vs 30.8%,P=0.03)。
- 干预期间总阿片类药物剂量显著降低(15.6 vs 8.5 静脉吗啡毫克当量/天,P=0.02)。
- 平均疼痛评分相似(3.9 vs 3.7,P=0.55),平均住院时间和30天再入院率显著降低。
核心结论
- 多模式干预与住院IBD患者阿片类药物暴露、住院时间和30天再入院率降低相关。
- 需要进一步研究以确定减少阿片类药物暴露在该人群中的长期获益。
研究设计与样本
- 前瞻性评估,纳入2019年1月1日至6月30日某大型城市学术医学中心普通内科病房住院的≥18岁IBD患者,并与2018年1月1日至12月31日干预前数据比较。
- 研究共涉及345例IBD患者,干预前241例,干预期间104例,基线特征相似。
主要发现
- 接受IVOPI的患者比例从干预前的43.6%降至干预期间的30.8%(P=0.03)。
- 总阿片类药物剂量暴露从干预前的15.6降至干预期间的8.5静脉吗啡毫克当量/天(P=0.02)。
- 平均疼痛评分干预前3.9 vs 干预期间3.7(P=0.55)。
- 平均住院时间干预前7.2天 vs 干预期间5.3天(P=0.03)。
- 30天再入院率干预前21.6% vs 干预期间11.5%(P=0.03)。
局限性
- 需要进一步研究以确定减少阿片类药物暴露在该人群中的长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Opioid use in patients with inflammatory bowel disease (IBD) is associated with increased mortality. Previous interventions targeting reduced intravenous opioid (IVOPI) exposure for all patients admitted to a general medical unit have decreased total opioid use without compromising pain control. We therefore performed a prospective evaluation of a multimodal intervention encouraging the use of nonopioid alternatives to reduce IVOPI exposure among patients with IBD hospitalized at our institution. METHODS: This was a prospective evaluation of a multimodal intervention to reduce IVOPI use among patients with IBD aged ≥18 years admitted to a general medical unit at a large urban academic medical center from January 1, 2019, to June 30, 2019. Intravenous and total (all routes) opioid exposures were measured as proportions and intravenous morphine milligram equivalents/patient day and compared with preintervention (January 1, 2018, to December 31, 2018) data. Hospital length of stay (LOS), 30-day readmission rates (RRs), and pain scores (1-10 scale) were also assessed. RESULTS: Our study involved 345 patients with IBD with similar baseline characteristics in preintervention (n = 241) and intervention (n = 104) periods. Between study periods, we observed a significant reduction in the proportion of patients receiving IVOPIs (43.6% vs 30.8%, P = 0.03) and total opioid dose exposure (15.6 vs 8.5 intravenous morphine mg equivalents/d, P = 0.02). We observed similar mean pain scores (3.9 vs 3.7, P = 0.55) and significantly reduced mean LOS (7.2 vs 5.3 days, P = 0.03) and 30-day RRs (21.6% vs 11.5%, P = 0.03). DISCUSSION: A multimodal intervention was associated with reduced opioid exposure, LOS, and 30-day RRs for hospitalized patients with IBD. Additional research is needed to determine long-term benefits of reduced opioid exposure in this population.
引用
- Dalal RS, Palchaudhuri S, Snider CK, et al. A Multimodal Intervention Using Nonopioid Analgesics Is Associated With Reduced Intravenous Opioid Exposure Among Hospitalized Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2020. PMID: 32796178. doi:10.14309/ajg.0000000000000806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。